Meme Kanseri İçin Nanotaşıyıcılar: Gelişmiş Perspektif

Abstract

Keywords

• breast cancer
• nanoparticles
• nano-drug delivery

Nanocarriers For Breast Cancer: Advanced Perspective

Abstract

Breast cancer is the form of cancer most prevalent and intensified progressively among the women population. The propagation of breast cancers takes place in different stages and diagnosed lately. Various approaches have been emerged to treat this clinical condition but these are also integrated with varied side effects. The reason might be attributed to undesired effects of the chemotherapeutic agent and/or haphazard damage to both healthy and cancerous cells. These hitches in- duce the urge for targeting cancerous cells by the utilization of novel therapeu- tic platforms. Nano-drug delivery systems are a cluster of different approaches to treating various severe diseases. Henceforward this concept is also applied in the treatment of breast cancer. Nanoparticles exhibits numerous benefits mainly, reduction in dose and low toxicity, solubility enhancement of certain drugs, in- creased cellular uptake etc. These are the efficient carrier of hydrophobic drugs as these drugs possess challenges in solubility and bioavailability. Cellular uptake by tumor cells is better by nanocarriers owing to a smaller size. The current review is aimed to through light on recent advances in nano-drug targeting in the manage- ment of breast cancer.

Keywords

• breast cancer
• nano-drug delivery
• nanocarriers

References

1. [1] Breast cancer facts & figures 2019-2020. Atlanta: American Cancer Society, Inc 2019.2019 Available online from: https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html
2. [2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians 2018,68:394-424.
3. [3] Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK: Various types and management of breast cancer: An overview. Journal of Advanced Pharmaceutical Technology and Research 2010,1 (2):109-26.
4. [4] Breast Cancer: Stages. Breast Cancer Guide.2020 Available online from: https://www.cancer.net/cancer-types/breast-cancer/stages
5. [5] Mathur P, Sathishkumar K, Chaturvedi M, Das P, Kondalli LS, Santhappan S, et al.: Cancer statistics, 2020: Report from national cancer registry programme, India. JCO Global Oncology 2020(6):1063-75.
6. [6] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians 2021,0:1-41.
7. [7] Breast Cancer Guide. Breast Cancer: Types of Treatment.2020 Available online from: https://www.cancer.net/cancer-types/breast-cancer/types-treatment
8. [8] Park K: Nanotechnology: What it can do for drug delivery. Journal of Controlled Release 2007,120 (1-2):1-3.

9. [9] Jagdale SC, Shah TP, Kuchekar BS, Chabukswar AR, Baviskar DT: Cancer Nanotechnology. Asian Journal of Pharmaceutics 2009:1-7.
10. [10] Jain RK, Stylianopoulos T: Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology 2010,7 (11):653-64.
11. [11] Sapra P, Tyagi P, Allen TM: Ligand-targeted liposomes for cancer treatment. Current Drug Delivery 2005,2 (4):369-81.
12. [12] Srinivasa GS, Yarema KJ: Dendrimers in Cancer Treatment and Diagnosis. In: Kumar CSSR, editor. Nanotechnologies for the Life Sciences, WILEY-VCH Verlag GmbH & Co. ; Weinheim: 2007. pp. 1-43.
13. [13] Kandekar UY, Chaudhari PD, Tambe VS, Vichare VS, Dhole SN: Dendrimers: novel drug nanocarriers. International Journal of Pharmaceutical Sciences and Research 2011,2 (5):1086.
14. [14] Marcinkowska M, Stanczyk M, Janaszewska A, Sobierajska E, Chworos A, Klajnert-Maculewicz B: Multicomponent conjugates of anticancer drugs and monoclonal antibody with PAMAM dendrimers to increase efficacy of HER-2 positive breast cancer therapy. Pharmaceutical Research 2019,36 (11):1-17.
15. [15] Kulhari H, Pooja D, Shrivastava S, Kuncha M, Naidu VGM, Bansal V, et al.: Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Scientific Reports 2016,6 (1):23179.
16. [16] Salimi M, Sarkar S, Hashemi M, Saber R: Treatment of breast cancer-bearing balb/c mice with magnetic hyperthermia using dendrimer functionalized iron-oxide nanoparticles. Nanomaterials 2020,10 (11):2310.
17. [17] Chittasupho C, Anuchapreeda S, Sarisuta N: CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition. European Journal of Pharmaceutics and Biopharmaceutics 2017,119:310-21.
18. [18] Jaiswal M, Dudhe R, Sharma PK: Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech 2015,5:123-7.
19. [19] Mendes Miranda SE, Alcântara Lemos Jd, Fernandes RS, Silva JdO, Ottoni FM, Townsend DM, et al.: Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model. Biomedicine & Pharmacotherapy 2021,133:110936.
20. [20] Salehi F, Behboudi H, Kavoosi G, Ardestani SK: Incorporation of Zataria multiflora essential oil into chitosan biopolymer nanoparticles: A nanoemulsion based delivery system to improve the in-vitro efficacy, stability and anticancer activity of ZEO against breast cancer cells. International journal of biological macromolecules 2020,143:382-92.
21. [21] Periasamy VS, Athinarayanan J, Alshatwi AA: Anticancer Activity of an Ultrasonic Nanoemulsion Formulation of Nigella sativa L. Essential Oil on Human Breast Cancer Cells. Ultrason Sonochem 2016,31:449-55.
22. [22] Migotto A, Carvalho VFM, Salata GC, da Silva FWM, Yan CYI, Ishida K, et al.: Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer. Drug Delivery 2018,25 (1):654-67.
23. [23] Saifuddin, Raziah NAZ, Junizah AR: Carbonnanotubes: A review on structure and their interaction with proteins. Journal of Chemistry 2013:1-18.
24. [24] De Volder MFL, Tawfick SH, Baughman RH, Hart AJ: Carbon nanotubes: present and future commercial applications. Science 2013,339:535-9.
25. [25] Tajabadi M: Application of carbon nanotubes in breast cancer therapy. Drug Research 2019:1-5.
26. [26] Edgar Pérez-Herrero, Alberto Fernández-Medarde: Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics 2015,93:52-79.
27. [27] Dizaji BF, Farboudi A, Rahbar A, Azarbaijan MH, Asgary MR: The role of single- and multi-walled carbon nanotube in breast cancer treatment. Therapeutic Delivery 2020,11 (10).
28. [28] Ozgen PSO, Atasoy S, Kurt BZ, Durmus Z, Yigit G, Dag A: Glycopolymer decorated multiwalled carbon nanotubes for dual targeted breast cancer therapy. Journal of Materials Chemistry B 2020,8 (15):3123-37.
29. [29] Badea MA, Prodana M, Dinischiotu A, Crihana C, Ionita D, Balas M: Cisplatin loaded multiwalled carbon nanotubes induce resistance in triple negative breast cancer cells. Pharmaceutics 2018,10 (4):228.
30. [30] Zhang H, Ji Y, Chen Q, Jiao X, Hou L, Zhu X, et al.: Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles. Journal of Drug Targeting 2015,23 (6):552-67
31. [31] Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M: Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 2005,21 (23):10644-54.
32. [32] Luna-Gutiérrez M, Ferro-Flores G, Ocampo-García BE, Santos-Cuevas CL, Jiménez-Mancilla N, León-Rodríguez D, et al.: A therapeutic system of 177Lu-labeled gold nanoparticles-RGD internalized in breast cancer cells. Journal of the Mexican Chemical Society 2013,57 (3):212-9.
33. [33] Kapara A, Brunton V, Graham D, Faulds K: Investigation of cellular uptake mechanism of functionalised gold nanoparticles into breast cancer using SERS. Chemical Science 2020,11 (22):5819-29.
34. [34] Abdolahinia ED, Nadri S, Rahbarghazi R, Barar J, Aghanejad A, Omidi Y: Enhanced penetration and cytotoxicity of metformin and collagenase conjugated gold nanoparticles in breast cancer spheroids. Life sciences 2019,231:116545.
35. [35] Vemuri SK, Rajkiran RB, Mukherjee S, Uppula P, Gpv S, Reddy GAV, et al.: Novel biosynthesized gold nanoparticles as anti-cancer agents against breast cancer: Synthesis, biological evaluation, molecular modelling studies. Materials Science and Engineering: C 2019,99:417-29.
36. [36] Rokade SS, Joshi KA, Mahajan K, Patil S, Tomar G, Dubal DS, et al.: Gloriosa superba mediated synthesis of platinum and palladium nanoparticles for induction of apoptosis in breast cancer. Bioinorganic Chemistry and Applications 2018,2018.
37. [37] Suganya UKS, Govindaraju K, Prabhu D, Arulvasu C, Karthick V, Changmai N: Anti-proliferative effect of biogenic gold nanoparticles against breast cancer cell lines (MDA-MB-231 & MCF-7). Applied Surface Science 2016,371:415-24.
38. [38] Khan SA, Kanwal S, Rizwan K, Shahid S: Enhanced antimicrobial, antioxidant, in vivo antitumor and in vitro anticancer effects against breast caner cell line by green synthesized un-doped SnO2 and Co-doped SnO2 nanoparticles from Clerodendrum inerme. Microbial Pathogenesis 2018,125:366-84.
39. [39] Nayak D, MinzAliva Prity , Ashe S, Rauta PR, Kumari M, chopra P, et al.: Synergistic combination of antioxidants, silver nanoparticles and chitosan in a nanoparticle based formulation: Characterization and cytotoxic effect on MCF-7 breast cancer cell lines. Journal of Colloid and Interface Science 2016,15 (470):142-52.
40. [40] Chang Y, Jiang J, Chen W, Yang W, Chen L: Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer. Applied Materials Today 2020,18:100492.
41. [41] Kumari A, Yadav SK, Yadav SC: Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and surfaces B: biointerfaces 2010,75 (1):1-18.
42. [42] Du M, Ouyang Y, Meng F, Ma Q, Liu H, Zhuang Y, et al.: Nanotargeted agents: an emerging therapeutic strategy for breast cancer. Nanomedicine 2019,14 (13):1771-86.
43. [43] Chen S-H, Liu T-I, Chuang C-L, Chen H-H, Chiang W-H, Chiu H-C: Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. Journal of Materials Chemistry B 2020,8 (17):3789-800.
44. [44] Hu C, Fan F, Qin Y, Huang C, Zhang Z, Guo Q, et al.: Redox-sensitive folate-conjugated polymeric nanoparticles for combined chemotherapy and photothermal therapy against breast cancer. Journal of Biomedical Nanotechnology 2018,14 (12):2018-30.
45. [45] Cho H-J, Yoon I-S, Yoon HY, Koo H, Jin Y-J, Ko S-H, et al.: Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 2012,33 (4):1190-200.
46. [46] Potineni A, Lynnb DM, Langerb R, Amiji MM: Poly(ethylene oxide)-modified poly(b-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. Journal of Controlled Release 2003,86:223-34.
47. [47] Khanna C, Rosenberg M, Vail DM: A review of paclitaxel and novel formulations including those suitable for use in dogs. Journal of Veterinary Internal Medicine 2015,29 (4):1006-12.
48. [48] Miele E, Spinelli GP, Miele E, Tomao F, Tomao S: Albumin-bound formulation of paclitaxel (Abraxane®ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine 2009,4:99-105.
49. [49] Chen S-H, Liu T-I, Chuang C-L, Chen H-H, Chiang W-H, Chiu H-C: Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. Journal of Material Chemisry B 2020,8 (17):3789-800.
50. [50] Zhou Y, Chen D, Xue G, Yu S, Yuan C, Huang M, et al.: Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA. Royal Society of Chemistry 2020,10 (57):34517–26 |.
51. [51] Jeon M, Lin G, Stephen ZR, Kato FL, Zhang M: Paclitaxel‐loaded iron oxide nanoparticles for targeted breast cancer therapy. Advanced Therapeutics 2019,2 (12):1900081.
52. [52] Zhong Y, Zhang J, Cheng R, Denga C, Meng F, Xie F, et al.: Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+human breast tumor xenografts. ournal of Controlled Release 2015,205:144–54.
53. [53] Li M, Tang Z, Zhang Y, Lv S, Li Q, Chen X: Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis. Acta Biomaterialia 2015,18:132-43.
54. [54] Maji R, Dey NS, Satapathy BS, Mukherjee B, Mondal S: Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy. International Journal of Nanomedicine 2014,9:3107.
55. [55] Manaspon C, Viravaidya-Pasuwat K, Pimpha N: Preparation of folate-conjugated pluronic f127/chitosan core-shellnanoparticles encapsulating doxorubicin for breast cancer treatment. Journal of Nanomaterials 2012:1-12.
56. [56] Abbasi S, Paul A, Shao W, Prakash S: Nanoparticles for targeted delivery of active agents against tumor cells. Journal of Drug Delivery 2012:1-8.
57. [57] Suna B, Ranganathana B, Fenga S-S: Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008,29:475–86.
58. [58] van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM: Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Molecular Pharmaceutics 2006,5 (4):516–26.
59. [59] Shubayev VI, Pisanic II TR, Jin S: Magnetic nanoparticles for theragnostics. Advanced Drug Delivery Reviews 2009,61 (6):467-77.
60. [60] Wang Y, Liu H, Yao D, Li J, Yang S, Zhang C, et al.: 18F-labeled magnetic nanoparticles for monitoring anti-angiogenic therapeutic effects in breast cancer xenografts. Journal of Nanobiotechnology 2019,17 (1):105.
61. [61] Nosrati H, Rashidi N, Danafar H, Manjili HK: Anticancer activity of tamoxifen loaded tyrosine decorated biocompatible Fe3O4 magnetic nanoparticles against breast cancer cell lines. Journal of Inorganic and Organometallic Polymers and Materials 2018,28 (3):1178-86.
62. [62] Natesan S, Ponnusamy C, Sugumaran A, Chelladurai S, Shanmugam Palaniappan S, Palanichamy R: Artemisinin loaded chitosan magnetic nanoparticles for the efficient targeting to the breast cancer. International journal of biological macromolecules 2017,104:1853-9.
63. [63] Yallapu MM, Othman SF, Curtis ET, Bauer NA, Chauhan N, Kumar D, et al.: Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. International Journal of Nanomedicine 2012,2 (7):1761-79.
64. [64] Poonia N, Lather V, Pandita D: Mesoporous silica nanoparticles: a smart nanosystem for management of breast cancer. Drug Discovery Today 2018,23 (2):315-32.
65. [65] Ali OM, Bekhit AA, Khattab SN, Helmy MW, Abdel-Ghany YS, Telebab M, et al.: Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy. Colloids and Surfaces B: Biointerfaces 2020,188:110824.
66. [66] Bhavsar D, Gajjar J, Sawant K: Formulation and development of smart pH responsive mesoporous silica nanoparticles for breast cancer targeted delivery of anastrozole: In vitro and in vivo characterizations. Microporous and Mesoporous Materials 2019,279:107-16.
67. [67] Mukherjee B, Chakraborty S, Mondal L, Satapathy BS, Sengupta S, Dutta L, et al.: Multifunctional drug nanocarriers facilitate more specific entry of therapeutic payload into tumors and control multiple drug resistance in cancer. In: Grumezescu AM, editor. Nanobiomaterials in Cancer Therapy, William Andrew Publishing: 2016. pp. 203-51. [68] Cho H, Lai TC, Tomoda K, Kwon GS: Polymeric micelles for multi-drug delivery in cancer. AAPS PharmSciTech, 2015,16 (1):10-20.
68. [69] Gener Paea: Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells. Nanimedicine: Nanotexhnology Biology and Medicine 2020,24:102106
69. [70] Xiang J, Wu B, Zhou Z, Hu S, Piao Y, Zhou Q, et al.: Synthesis and evaluation of a paclitaxel-binding polymeric micelle for efficient breast cancer therapy. Science China Life Sciences 2018,61 (4):436-47.
70. [71] Tan L, Ma B, Chen L, Peng J, Qian Z: Toxicity evaluation and anti-tumor study of docetaxel loaded mPEG-polyester micelles for breast cancer therapy. Journal of Biomedical Nanotechnology 2017,13 (4):393-408.
71. [72] Bothiraja C, Kapare HS, Pawar AP, Shaikh KS: Development of plumbagin-loaded phospholipid–Tween®80 mixed micelles: formulation, optimization, effect on breast cancer cells and human blood/serum compatibility testing. Therapeutic Delivery 2013,4 (10):1247–59.
72. [73] Lecot N, Glisoni R, Oddone N, Benech J, Fernández M, Gambini JP, et al.: Glucosylated polymeric micelles actively target a breast cancer model. Advanced Therapeutics 2021,4 (1):2000010.
73. [74] Cui Y, Yang Y, Ma M, Xu Y, Sui J, Li H, et al.: Reductive responsive micelle overcoming multidrug resistance of breast cancer by co-delivery of DOX and specific antibiotic. Journal of Material Chemisry B 2019,7 (40):6075-86.
74. [75] Zhang Y, Zhu X, Chen X, Chen Q, Zhou W, Guo Q, et al.: Activated platelets‐targeting micelles with controlled drug release for effective treatment of primary and metastatic triple negative breast cancer. Advaced Functional Materials 2019,29 (13):1806620.
75. [76] Kesharwani SS, Dachineni R, Bhat GJ, Tummala H: Hydrophobically modified inulin-based micelles: Transport mechanisms and drug delivery applications for breast cancer. Journal of Drug Delivery Science and Technology 2019,54:101254.
76. [77] Wang J, De G, Yue Q, Ma H, Cheng J, Zhu G, et al.: pH Responsive Polymer Micelles Enhances Inhibitory Efficacy on Metastasis of Murine Breast Cancer Cells. Frontiers in Pharmacology 2018,9 (543).
77. [78] Pawar A, Singh S, Rajalakshmi S, Shaikh K, Bothiraja C: Development of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting. Artif Cells Nanomed Biotechnol 2018,46 (sup1):347-61.
78. [79] Ji W, Wang B, Fan Q, Xu C, He Y, Chen Y: Chemosensitizing indomethacin-conjugated dextran-based micelles for effective delivery of paclitaxel in resistant breast cancer therapy. PLoS ONE 2017,12 (7):0180037.
79. [80] Wang Y, Wang Y, Chen G, Li Y, Xu W, Gong S: Quantum-dot-based theranostic micelles conjugated with an anti-EGFR nanobody for triple-negative breast cancer therapy. ACS Applied Materials & Interfaces 2017,9 (36):30297-305.
80. [81] Tang S, Meng Q, Sun H, Su J, Yin Q, Zhang Z, et al.: Dual pH-sensitive micelles with charge-switch for controlling cellular uptake and drug release to treat metastatic breast cancer. Biomaterials 2017,114:44-53.
81. [82] Hassanzadeh F, Varshosaz J, Khodarahmi GA, Rostami M, Hassanzadeh F: Biotin-encoded pullulan-retinoic acid engineered nanomicelles: Preparation, optimization and in vitro cytotoxicity assessment in MCF-7 cells. Indian Journal of Pharmaceutical Sciences 2016,78 (5):557-65.
82. [83] Brinkman AM, Chen G, Wang Y, Hedman CJ, Sherer NM, Havighurst TC, et al.: Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials 2016,101:20-31.
83. [84] Yu H, Cui Z, Yu P, Guo C, Feng B, Jiang T, et al.: pH‐and NIR light‐responsive micelles with hyperthermia‐triggered tumor penetration and cytoplasm drug release to reverse doxorubicin resistance in breast cancer. Advanced Functional Materials 2015,25 (17):2489-500.
84. [85] Wang T, Yang S, A. ML, Parmar CK, Gillespie JW, Praveen KP, et al.: Paclitaxel-loaded peg-pe–based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors. Molecular Cancer Therapeutics 2014,13 (12):2864-75.
85. [86] Zhang X-y, Zhang P-y: Polymersomes in Nanomedicine - A Review Current Nanoscience 2017,13:124-9.
86. [87] Zavvar T, Babaei M, Abnous K, Taghdisi SM, Nekooei S, Ramezani M, et al.: Synthesis of multimodal polymersomes for targeted drug delivery and MR/fluorescence imaging in metastatic breast cancer model. International Journal of Pharmaceutics 2020,578:119091.
87. [88] Shahriari M, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M: Synthesis of hyaluronic acid-based polymersomes for doxorubicin delivery to metastatic breast cancer. International Journal of Pharmaceutics 2019,572:118835.
88. [89] Abolfazl Akbarzadeh, Rogaie Rezaei-Sadabady, Soodabeh Davaran, Sang Woo Joo, Nosratollah Zarghami, Younes Hanifehpour, et al.: Liposome: classification, preparation, and applications. Nanoscale Research Letters 2013,8:102.
89. [90] Lee J-Y, Shin DH, Kim J-S: Anticancer effect of metformin in herceptin-conjugated liposome for breast cancer. Pharmaceutics 2020,12 (1):11.
90. [91] Shukla SK, Kulkarni NS, Chan A, Parvathaneni V, Farrales P, Muth A, et al.: Metformin-encapsulated liposome delivery system: an effective treatment approach against breast cancer. Pharmaceutics 2019,11 (11):559.
91. [92] Shemesh CS, Moshkelani D, Zhang H: Thermosensitive liposome formulated indocyanine green for near-infrared triggered photodynamic therapy: In vivo evaluation for triple-negative breast cancer. Pharmaceutical Research 2015,32:1604–14.
92. [93] Coscoa D, Paolinoa D, Cilurzoa F, Casalea F, Frestaa M: Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. International Journal of Pharmaceutics 2012,422:229– 37.
93. [94] Chowdhury N, Chaudhry S, Hall Nea: Targeted delivery of doxorubicin liposomes for HER-2+ breast cancer treatment. AAPS PharmSciTech 2020,21 (202).
94. [95] Fu M, Tang W, Liu J-J, Gong X-Q, Kong L, Yao X-M, et al.: Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer. Journal of Drug Targeting 2020,28 (3):245-58.
95. [96] Zhao YN, Cao YN, Sun J, Liang Z, Wu Q, Cui SH, et al.: Anti-breast cancer activity of resveratrol encapsulated in liposomes. Journal of Material Chemisry B 2020,8 (1):27-37.
96. [97] Ghafari M, Haghiralsadat F, Khanamani S, pour F, Reza JZ: Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy. Journal of Cellular Biochemistry 2020,121 (7):3584-92.
97. [98] Okamoto Y, Taguchi K, Imoto S, Chuang VTG, Yamasaki K, Otagiri M: Cell uptake and anti-tumor effect of liposomes containing encapsulated paclitaxel-bound albumin against breast cancer cells in 2D and 3D cultured models. Journal of Drug Delivery Science and Technology 2020,55:101381.
98. [99] Gheybi F, Alavizadeh SH, Rezayat SM, Zendedel E, Jaafari M: Chemotherapeutic activity of Silymarin combined with doxorubicin liposomes in 4T1 breast cancer cells. Nanomedicine Research Journal 2019,4 (1):29-34.
99. [100] Alexander P, Jainamboo M, Praseetha PK, Gopukumar ST: Silica coated liposomes for drug delivery towards breast cancer cells. Rasayan Journal of Chemistry 2016,9 (3):300 - 8.
100. [101] Jadia R, Kydd J, Piel B, Rai P: Liposomes aid curcumin's combat with cancer in a breast tumor model. Oncomedicine 2018,3:94-109.
101. [102] Cao J, Wang R, Gao N, Li M, Tian X, Yang W, et al.: A7RC peptide modified paclitaxel liposomes dually target breast cancer. Biomaterials Science 2015,3 (12):1545-54.
102. [103] Ağardan NBM, Değim Z, Yılmaz Ş, Altıntaş L, Topal T: The effectiveness of raloxifene-loaded liposomes and cochleates in breast cancer therapy. AAPS PharmSciTech 2016,17 (4):968-77.
103. [104] Dadgar N, Esfahani MKM, Torabi S, Alavi SE, Akbarzadeh A: Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer. Indian Journal of Clinical Biochemistry 2014,29 (4):501-4.
104. [105] Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Bawab AAl: Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Delivery 2012,19 (8):371-7.
105. [106] Pindiprolu SKSS, Chintamaneni PK, Krishnamurthy PT, Ganapathineedi KRS: Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells. Drug Development and Industrial Pharmacy 2019,45 (2):304-13.
106. [107] Guney EG, Cecener G, Dikmen G: Solid lipid nanoparticles: reversal of tamoxifen resistance in breast cancer. European Journal of Pharmaceutical Sciences 2018,120:73-88.
107. [108] Mehnert W, Mader K: Solid lipid nanoparticles: production, characterization and applications. Advance Drug Delivery Review 2001,47:165-96.
108. [109] Soni NK, Sonali LJ, Singh A, Mangla B, Neupane YR, Kohli K: Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment. Nanotechnology 2020,31 (47):475101.
109. [110] Zafar S, Akhter S, Ahmad I, Hafeeze Z, Rizvi MAM, Jain GK, et al.: Improved chemotherapeutic efficacy against resistant human breast cancer cells with co-delivery of Docetaxel and Thymoquinone by Chitosan Grafted Lipid Nanocapsules: Formulation optimization, in vitro and in vivo studies. Colloids and Surfaces B: Biointerfaces 2020,186:110603.
110. [111] Miller WHJ, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of action of arsenic trioxide. Cancer Research 2002,62:3893–903.
111. [112] Ahn RW, Chen F, Chen H, Stern ST, Clogston JD, Patri AK, et al.: A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clinical Cancer Research 2010,16 (14):3607-17.
112. [113] Chen H, MacDonald RC, Li S, Krett NL, Rosen ST, O’Halloran TV: Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. Journal of american Chemical Society 2006,128:13348-9.
113. [114] Agarwal A, Ng WJ, Liu Y: Principle and applications of microbubble and nanobubble technology for water treatment. Chemosphere 2011,84 (9):1175-80.
114. [115] Hui J, Wen C, Shouqiang L, Bolin W, Xiaoping L, Shouping X, et al.: Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy. Colloids and Surfaces B: Biointerfaces 2016,146:387–95.
115. [116] Mahjour A, Khazaei M, Nourmohamadi E, Sarkarizi HK: Evaluation of antitumor effect of oxygen nanobubble water on breast cancer‐bearing BALB/c mice. Journal of Cellular Biochemistry 2019,120 (9):15546-52.